A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Major depressive disorder is a serious, recurrent and disabling mental disorder, which is the second leading cause of years lost to disability worldwide. Accumulating evidence suggests the important role for inflammation and oxidative stress in the pathophysiology of depression. Sulforaphane extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. Previous studies suggested sulforaphane activates Keap1-Nrf2 system to prevent depression-like phenotype in mice. In this study, the investigator attempts to evaluate the efficacy, safety, and tolerability of sulforaphane plus a fixed oral antipressant in adult participants diagnosed with depression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central South University
• Treatments: Citalopram; Dexetimide; Sulforafan; Sulforaphane

Criteria

Inclusion Criteria:

• 18-55 years old

• Clinical diagnosis of recurrent MDD or single-episode MDD with MADRS≥22, CGI-SI≥4

• be adherent to the continued oral antidepressant treatment medication

Exclusion Criteria:

• treatment-resistant depression

• have known allergies, hypersensitivity, intolerance, or contraindications to SSRI or any of the trial preparations

• strong homicidal ideation/intent

• pregnancy